# Harbin Gloria Pharmaceuticals

Harbin Gloria Pharmaceuticals is a Corporate Investor based in Beijing, China.

## Overview

- **Organization type:** Corporate Investor
- **Headquarters:** Beijing, China
- **Region:** Asia
- **Address:** Beijing, China
- **Founded:** 2000
- **Assets under management:** Undisclosed
- **Website:** gloria.cc
- **LinkedIn:** https://www.linkedin.com/company/harbin-gloria-pharmaceuticals-co-ltd

## Regulatory record

- **Reports private funds:** No

## About

Founded in 2000 by Zhu Jiman, Harbin Gloria Pharmaceuticals listed on the Shenzhen Stock Exchange in 2010 and built its original balance sheet through domestic generics, R&D, and marketing. A decisive restructuring transferred operational control to Harbin Pharmaceutical Group Co., Ltd., which now holds a 42.47% institutional stake—an architecture that blends state-backed distribution muscle with legacy private pharmaceutical entrepreneurship. Gloria Biotechnology serves as the firm's principal investment and acquisition arm, targeting clinical-stage and commercial biotech assets across China. The platform co-invests with a tight circle of institutional partners: Hony Capital brings private equity scale, Boyu Capital contributes cross-border healthcare expertise, and 6 Dimensions Capital adds sector-specialist scientific diligence. Confirmed therapeutic areas span oncology, immunology, and advanced drug delivery systems, with a structural preference for majority or joint-control positions rather than passive minority stakes. Beyond biotech, the firm holds a real estate and other assets portfolio within China, reflecting a corporate treasury function that originated during the pre-restructuring era. Chairwoman Shen Zhenyu, the single largest individual shareholder at approximately 4.92%, navigates the firm's hybrid identity—part state-adjacent corporate investor, part serial biotech consolidator. Harbin Gloria's structural differentiator is its hybrid governance: a publicly listed corporate shell, a dominant state-owned enterprise shareholder, and a co-investment club of blue-chip private equity firms executing biotech roll-ups through a dedicated subsidiary. This architecture lets it access public-market liquidity and SOE procurement channels while moving at private-deal speed in a sector where most pure-play Chinese pharma investors are either fully private or fully state-run.

## Sectors

- Healthcare Services
- Industrial Tech

## People

- Shen Zhenyu — Chairwoman
- Zhu Jiman — Founder

## Questions

### Who controls Harbin Gloria Pharmaceuticals?

Harbin Pharmaceutical Group Co., Ltd. is the dominant institutional shareholder with a 42.47% stake. Chairwoman Shen Zhenyu is the single largest individual shareholder at approximately 4.92%. Founder Zhu Jiman was the original controller before the restructuring that brought in the state-owned enterprise as the majority institutional backer.

### What is the relationship between Harbin Gloria and Harbin Pharmaceutical Group?

Harbin Pharmaceutical Group Co., Ltd., a state-owned enterprise, holds a 42.47% stake in Harbin Gloria Pharmaceuticals, making it the controlling institutional shareholder. This relationship gives the listed corporate investor access to state-backed distribution networks and procurement channels while retaining its public-company structure and co-investment partnerships with private equity firms.

### Does Harbin Gloria operate purely as a pharmaceutical company or also as an investment firm?

It operates as a hybrid: a Shenzhen-listed pharmaceutical company with an operating business in drug R&D, production, and marketing, and a corporate investment platform through Gloria Biotechnology. The investment arm makes direct acquisitions and co-investments in biotech assets, functioning similarly to a corporate venture and growth equity platform embedded within a public company.

### Which external investment partners does Harbin Gloria work with?

Three named co-investors participate alongside Gloria Biotechnology: Hony Capital, a major China-focused private equity firm; Boyu Capital, which brings cross-border healthcare transaction expertise; and 6 Dimensions Capital, a sector-specialist healthcare and life sciences investor. This co-investment club operates as the firm's primary external capital and diligence network.

## Related profiles

- [Harbin Boshi Automation](https://altss.com/profile/harbin-boshi-automation)
- [Harbin Investment Group](https://altss.com/profile/harbin-investment-group)

---

Last updated: 2026-08-11T02:43:31.692Z

Canonical page: https://altss.com/profile/harbin-gloria-pharmaceuticals

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology